NIKKEI 225
37,628.48 -831.60 (-2.16%) HANG SENG
17,284.54 +83.27 (+0.48%) CRUDE OIL
82.56 -0.25 (-0.30%) GOLD FUTURES
2,339.60 +1.20 (+0.05%) DOW
37,979.74 -481.18 (-1.25%) Bitcoin GBP
51,350.20 -356.31 (-0.69%)
Northwest Biotherapeutics, Inc. (NWBO)
| Previous close | 0.4601 |
| Open | 0.4700 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.4601 - 0.4870 |
| 52-week range | 0.4000 - 1.0900 |
| Volume | |
| Avg. volume | 1,731,627 |
| Market cap | 567.616M |
| Beta (5Y monthly) | -0.70 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0600 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireNorthwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has appointed Mr. Pat Sarma to its Board of Directors effective March 18, 2024.
- PR Newswire
Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the key development work for the Flaskworks manufacturing system has been completed and an external vendor has been engaged to produce GMP-grade units of the system. In addition, the patent coverage of the Flaskworks system has been expanded: the foundational patent has been issued in the U.S. (and elsewhere) and an additional n
- PR Newswire
Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that a Marketing Authorization Application (MAA) was submitted yesterday to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax®-L for glioblastoma brain cancer.
